Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Breast Cancer-Related Lymphedema Occurs More Often in Black Women vs White Women

December 7, 2021
By Ryan McDonald
News
Article
Conference|San Antonio Breast Cancer Symposium (SABCS)

Black women with breast cancer had a 3.5-fold higher rate of lymphedema over 24 months compared with White women.

Black women with breast cancer who were treated with axillary lymph node dissection (ALND) and radiotherapy had a 3.5-fold higher chance of developing lymphedema compared with White women, according to a presentation from the 2021 San Antonion Breast Cancer Symposium.

The results also indicated that Hispanic women have a 3-fold increased incidence of breast cancer-related lymphedema compared with White women. However, Andrea V. Barrio, MD, FACS, an associate attending physician in the Breast Service, Department of Surgery, at Memorial Sloan Kettering Cancer Center, noted that more data is needed to confirm this observation.

“Notably, the number of Hispanic women in our study was small,” Barrio, the study’s lead author, explained while presenting the data during a press briefing.

At the beginning of her presentation, Barrio noted that results from epidemiological studies have shown that Black women with breast cancer have an increased susceptibility to developing lymphedema. However, as she discussed, there is very little prospective clinical trial data confirming those results.

“The aim of our study was to assess the incidence of lymphedema in a prospective cohort of patients treated with axillary lymph node dissection to identify risk factors associated with lymphedema development and to evaluate the impact of race and ethnicity on lymphedema incidence and severity,” she said.

To evaluate this incidence, Barrio and her colleagues enrolled 827 women aged 18 years and older with breast cancer. Enrolled patients also had to have received a unilateral ALND either in the primary setting or after a sentinel lymph node biopsy to be eligible to be included in the analysis.

The study authors collected bilateral arm measurements using a perometer. The patients had these measurements taken at baseline, post-op and every 6 months for 2 years. A relative increase in a patient’s arm volume of 10% or greater from baseline indicated the presence of lymphedema.

After accounting for ineligible criteria, the final study enrollment comprised of 276 patients (median age, 48 years; range, 40-57 years) who had at least 1 longitudinal measurement after baseline.

More than half (60%) of the patient population was White. The remaining patient population makeup included 20% Black, 11% Asian and 6% Hispanic. Additionally, 68% of the patient population presented to the study with HR+/HER2- disease. Nineteen percent of the patients were diagnosed with HER2+ disease and 13% of the population had HR-/HER2- disease. Seventy percent of the study population received neoadjuvant chemotherapy, while the rest underwent upfront surgery. Almost all (94%) of the patients who had upfront surgery and underwent systemic chemotherapy received a taxane-containing regimen, Barrio explained.

The treatment characteristics also indicated that 95% of patients received radiotherapy and 93% of patients received nodal RT.

When assessing clinical characteristics by race and ethnicity, White and Black women were older (median age, 49 years, respectively). Black (30.3 kg/m2) and Hispanic (28.1 kg/m2) patients had a higher baseline BMI compared with the White (25.2 kg/m2) and Asian (22.2 kg/m2) patient populations.

At a median follow-up of 22.6 months, 56 patients developed lymphedema. The results demonstrated that the 12-month lymphedema rate was 8.8% (95% CI; 5.9-13), and that the 24-month lymphedema rate was 24.7% (95% CI; 19.2-31.5%).

Barrio noted that the highest incidence of lymphedema observed was among Black women with a 24-month lymphedema rate of 39.4%. That rate was compared with 27.7% in Hispanic women, 23.4% in Asian women and 20.5% in White women.

The results also showed that receipt of neoadjuvant chemotherapy was associated with a higher 24-month lymphedema rate compared to upfront surgery at 30.9% vs. 11.1% (P = .0066).

The highest incidence of lymphedema observed among Black women with a 24 month lymphedema rate of 39% compared to 28% in Hispanic women, 23% in Asian women and 21% in white women.

Of note, Barrio said, among women with lymphedema, lymphedema severity did not vary across racial and ethnic groups with similar relative volume changes observed.

“We observed a higher incidence of lymphedema in black women treated with axillary lymph node dissection and radiotherapy after adjustment for other variables. Similar findings were observed in Hispanic women but confirmation in a larger data set is needed,” she said.

Barrio also highlighted how neoadjuvant chemotherapy was associated with a significant increase in lymphedema compared with adjuvant therapy in women who received ALND and RT.

As a result, Barrio concluded, “We postulate that neoadjuvant chemotherapy may cause fibrosis of tumor-filled lymphatics, as well as lymphatic endothelial damage prior to surgery, resulting in the higher lymphedema incidents observed in our study.

“In patient subsets unlikely to achieve a nodal pathologic complete response with neoadjuvant chemotherapy, alternatives to NAC to avoid ALND are needed. The etiology for the higher observed incidence of lymphedema and black women is largely unknown, but maybe due to race-based differences and inflammatory reactions, tissue fibrosis and lymphatic function. Future studies should address the biologic mechanisms behind racial disparities in lymphedema development.”

Reference

Barrio AV, et al. Impact of race and ethnicity on incidence and severity of breast cancer related lymphedema after axillary lymph node dissection: Results of a prospective screening study. Presented at: 2021 San Antonia Breast Cancer Symposium; December 7-10, 2021; Virtual. Abstract GS4-01

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content
Advertisement

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

Radhika Appaya;Erika P. Hamilton, MD;Thomas Decker;Hope S. Rugo, MD;Maria Fernandez Abad;Kevin Kalinsky, MD, MS;Qiang Liu;Mariya Rozenblit, MD;Barbara Radecka;Seock-Ah Im;Frances Visco;Alejandro Perez;Yogesh Chattar;Murat Akdere;Vaidyanathan Ganapathy;Sorcha Waters;Joyce O’Shaughnessy, MD
June 27th 2025
Article


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment

ONCOLOGY Staff
June 26th 2025
Article

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.


Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

225AC-3BP-3940 Is Safe, Shows Activity in Heavily Pretreated Advanced Breast Cancer

Gina Mauro
June 24th 2025
Article

Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.


23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

Radhika Appaya;Nicholas McAndrew;Stephen Chia;Fabio Puglisi;Aditya Bardia, MD, MPH;Yann Izarzugaza;Christian Schem, MD;Binghe Xu;Fanny Le Du;Priyanka Sharma, MD;Karen Afenjar;Murat Akdere;Juan Pablo Zarate;Yogesh Chattar;Peter A. Fasching
June 23rd 2025
Article

Related Content
Advertisement

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

Radhika Appaya;Erika P. Hamilton, MD;Thomas Decker;Hope S. Rugo, MD;Maria Fernandez Abad;Kevin Kalinsky, MD, MS;Qiang Liu;Mariya Rozenblit, MD;Barbara Radecka;Seock-Ah Im;Frances Visco;Alejandro Perez;Yogesh Chattar;Murat Akdere;Vaidyanathan Ganapathy;Sorcha Waters;Joyce O’Shaughnessy, MD
June 27th 2025
Article


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment

ONCOLOGY Staff
June 26th 2025
Article

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.


Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

225AC-3BP-3940 Is Safe, Shows Activity in Heavily Pretreated Advanced Breast Cancer

Gina Mauro
June 24th 2025
Article

Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.


23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

Radhika Appaya;Nicholas McAndrew;Stephen Chia;Fabio Puglisi;Aditya Bardia, MD, MPH;Yann Izarzugaza;Christian Schem, MD;Binghe Xu;Fanny Le Du;Priyanka Sharma, MD;Karen Afenjar;Murat Akdere;Juan Pablo Zarate;Yogesh Chattar;Peter A. Fasching
June 23rd 2025
Article

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.